These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 23690288)

  • 1. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.
    Townsley DM; Desmond R; Dunbar CE; Young NS
    Int J Hematol; 2013 Jul; 98(1):48-55. PubMed ID: 23690288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biology of thrombopoietin and thrombopoietin receptor agonists.
    Kuter DJ
    Int J Hematol; 2013 Jul; 98(1):10-23. PubMed ID: 23821332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guest editorial: Pathophysiology and management of thrombocytopenia: possible clinical application of TPO receptor agonists.
    Tomiyama Y
    Int J Hematol; 2013 Jul; 98(1):8-9. PubMed ID: 23793996
    [No Abstract]   [Full Text] [Related]  

  • 4. Eltrombopag in chronic hepatitis C.
    Mihăilă RG; Cipăian RC
    World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.
    Pecci A
    Int J Hematol; 2013 Jul; 98(1):34-47. PubMed ID: 23636669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2014.
    Visconte V; Lindsley RC; Berlyne D
    Leuk Res; 2015 Jan; 39(1):110-3. PubMed ID: 25435026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology and management of primary immune thrombocytopenia.
    Kashiwagi H; Tomiyama Y
    Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
    N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.
    Rodeghiero F; Carli G
    Ann Hematol; 2017 Sep; 96(9):1421-1434. PubMed ID: 28275823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
    Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
    Elife; 2021 Jun; 10():. PubMed ID: 34059198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
    Fattizzo B; Levati G; Cassin R; Barcellini W
    Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
    Zhang X; Chuai Y; Nie W; Wang A; Dai G
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016.
    Zeidan AM; Battiwalla M; Berlyne D; Winkler T
    Leuk Res; 2017 Feb; 53():8-12. PubMed ID: 27923195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.
    Beyar-Katz O; Perry C; On YB; Amit O; Gutwein O; Wolach O; Kedar R; Pikovsky O; Avivi I; Gold R; Ben-Ezra J; Shasha D; Ami RB; Ram R
    Ann Hematol; 2022 Aug; 101(8):1769-1776. PubMed ID: 35731278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to Acquired and Inherited Bone Marrow Failure.
    Sieff CA
    Hematol Oncol Clin North Am; 2018 Aug; 32(4):569-580. PubMed ID: 30047411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of the absolute immature platelet number reflects marrow production and is not impacted by platelet transfusion.
    Bat T; Leitman SF; Calvo KR; Chauvet D; Dunbar CE
    Transfusion; 2013 Jun; 53(6):1201-4. PubMed ID: 23043309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome.
    Sharathkumar A; Carr J; Claassen D; Syrbu S; Bhagavathi S; Al-Huniti A; Modi A; Bates M; Mott SL
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):252-261. PubMed ID: 38787686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Change in paradigm in the treatment of pediatric acquired bone marrow failure syndromes in Hungary].
    Kállay K; Csomor J; Ádám E; Bödör C; Kassa C; Simon R; Kovács G; Péter G; Ottóffy G; Bartyik K; Kiss C; Masát P; Réti M; Tóth B; Kriván G
    Orv Hetil; 2018 Oct; 159(42):1710-1719. PubMed ID: 30334483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.